February 09, 2022
Article
Larotrectinib was the first drug to receive accelerated FDA approval for patients of all ages based on a common molecular marker, independent of tissue origin for targeted therapy.
November 30, 2021
Olaparib was the first PARP inhibitor to be developed and has been the most studied.
November 16, 2021
The FDA initially approved regorafenib for chemorefractory metastatic colorectal cancer and unresectable gastrointestinal stromal tumor in 2012.
October 28, 2021
Common and debilitating, the mental health condition is often underdiagnosed and undertreated.
July 28, 2021
AQP-modulating agent discovery has proved challenging, but many powerful AQP3 permeating molecules have been identified.
July 08, 2021
A recent study proved community pharmacies are model settings for skin cancer prevention education in rural communities with insufficient access to health care services.